Skip to main content
. Author manuscript; available in PMC: 2024 Jul 3.
Published in final edited form as: Int J Gynecol Cancer. 2023 Mar 6;33(3):351–357. doi: 10.1136/ijgc-2022-003675

Figure 2.

Figure 2

Food and Drug Administration approvals summary for immune checkpoint inhibitors based on microsatellite instability and tumor mutational burden status in solid tumors. *KEYNOTE-16; **KEYNOTE-158; ***KEYNOTE-146 and KEYNOTE-775; §CheckMate142; !Garnet. CRC, colorectal cancer; dMMR, deficient mismatch repair; MSI-H, microsatellite instability-high; MSS, microsatellite stable; TMB, tumor mutational burden.